Physician profile
James A Wallace
NPI 1669687307
$228,820.56
in general payments reported to CMS, 2019-2025
42 companies · $22K in 2025
The $22K reported for 2025 was more than what 89% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $13K · 2021: $26K · 2022: $38K · 2023: $41K · 2024: $15K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Travel and Lodging: $7,423 · Food and Beverage: $4,640 · Consulting Fee: $407 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,410.00 |
| Travel and Lodging | $7,423.15 |
| Food and Beverage | $4,639.93 |
| Consulting Fee | $406.96 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $146,607.87 | 2020-2025 | |
| Genentech USA, INC. | $78,620.08 | 2019-2025 | Venclexta, Polivy, Tecentriq Hybreza |
| Novartis Pharmaceuticals Corporation | $596.87 | 2023-2025 | |
| Celgene Corporation | $367.16 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $282.41 | 2021-2025 | Calquence, Enhertu, Lynparza |
| Gilead Sciences, INC. | $264.56 | 2021-2025 | Trodelvy |
| Pfizer INC. | $235.96 | 2024-2025 | |
| Incyte Corporation | $180.63 | 2025 | Jakafi |
| Amgen INC. | $161.71 | 2023 | Nplate, Vectibix, Xgeva |
| Janssen Biotech, INC. | $123.70 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Glaxosmithkline, LLC. | $109.16 | 2024-2025 | Ojjaara, Blenrep, Zejula |
| Abbvie INC. | $106.13 | 2024-2025 | |
| Sobi, INC | $98.25 | 2024-2025 | |
| Tempus Ai, INC | $92.81 | 2024 | |
| Cardinal Health 414 LLC | $82.46 | 2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $78.62 | 2025 | Braftovi, Mektovi, Tukysa |
| Daiichi Sankyo INC. | $69.40 | 2024-2025 | Enhertu, Injectafer |
| Eisai INC. | $66.90 | 2025 | |
| Exelixis INC. | $58.16 | 2025 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $55.14 | 2024-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $47.50 | 2022-2023 | Keytruda, Lynparza |
| Janssen Pharmaceuticals, INC | $42.12 | 2021 | |
| Myriad Genetic Laboratories, INC. | $42.07 | 2021-2022 | |
| Astellas Pharma US INC | $41.16 | 2024-2025 | Padcev, Xtandi |
| Alexion Pharmaceuticals, INC. | $41.01 | 2024-2025 | Ultomiris |
| Geron Corporation | $34.11 | 2025 | Rytelo |
| Genzyme Corporation | $31.13 | 2025 | |
| Intera Oncology, INC | $30.30 | 2025 | Intera |
| Karyopharm Therapeutics INC. | $30.05 | 2021 | |
| Acrotech Biopharma INC. | $27.56 | 2023 | Beleodaq |
| Braintree Laboratories, INC. | $27.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.04 | 2025 | |
| Seagen INC. | $26.06 | 2023 | Padcev |
| Morphosys, US INC. | $21.95 | 2021 | |
| Puma Biotechnology, INC. | $20.39 | 2025 | |
| Rigel Pharmaceuticals, INC. | $19.22 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Emd Serono, INC. | $18.48 | 2024 | |
| Recordati_rare_diseases_inc. | $18.36 | 2025 | Enjaymo |
| Stemline Therapeutics INC. | $16.91 | 2025 | Orserdu |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.